Floatz logo

Cefepime

Neutropenia

Hospital Universitari Vall d'Hebron Research InstituteSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

17 Active assets in the Neutropenia cohort.

Asset / SponsorPhaseRating
f-627
EVIVE Biotechnology
Phase 3BBB
FILGRASTIM
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 4BBB
PEGFILGRASTIM
Affiliated Hospital of North Sichuan Medical College
Phase 4BBB
Spi-2012
Spectrum Pharmaceuticals, Inc
Phase 3BB
Cyclophosphamide
Spectrum Pharmaceuticals, Inc
Phase 3BB

View all 50 →

Same molecule, other indications

Cefepime is also rated in:

Invasive Bacterial InfectionDormant
B
Indicative ·
62 / 100
View asset →
Pediatric CancerDormant
B
Indicative ·
62 / 100
View asset →
Fever, Sweats, and Hot FlashesDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →